Grove Bank & Trust Has $241,000 Stock Holdings in Sanofi (NASDAQ:SNY)

Grove Bank & Trust lowered its position in shares of Sanofi (NASDAQ:SNY) by 12.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,000 shares of the company’s stock after selling 691 shares during the quarter. Grove Bank & Trust’s holdings in Sanofi were worth $241,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in SNY. Charles Schwab Investment Management Inc. grew its position in Sanofi by 31.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after purchasing an additional 33,105 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after acquiring an additional 16,780 shares during the last quarter. GFS Advisors LLC raised its holdings in Sanofi by 1,017.9% during the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock worth $738,000 after acquiring an additional 11,655 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after purchasing an additional 399,301 shares during the last quarter. Finally, Legacy Capital Wealth Partners LLC increased its position in shares of Sanofi by 114.2% during the 3rd quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock worth $1,399,000 after purchasing an additional 12,942 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $50.74 on Monday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average price is $48.46 and its two-hundred day moving average price is $52.11. The company has a market cap of $128.77 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 1.17 and a beta of 0.57. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period in the previous year, the firm earned $2.55 EPS. The firm’s revenue was up 12.3% compared to the same quarter last year. On average, analysts predict that Sanofi will post 3.94 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.